Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Patients With Stable Atherothrombotic Disease

NCT01499420 is registered in ClinicalTrials.gov with CSL Limited as lead sponsor.

NCT NCT01499420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01499420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Patients With Stable Atherothrombotic Disease
Lead sponsor
CSL Limited
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2012
Completion date
March 31, 2013
Enrollment
45 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

stable atherothrombotic disease